Shuwen Biotech has announced that PerkinElmer will distribute its preeclampsia test in 100 countries worldwide.
Preeclampsia affects between 2 and 8 per cent of global pregnancies, representing the number one cause of maternal death in some parts of the world.
Often, the symptoms are not noticeable until it has significantly progressed, with an urgent need for an effective test.
The Shuwen test is urine-based and non-invasive, producing a result in under three minutes. Clinical testing has shown the test to be over 95 per cent accurate in diagnosing preeclampsia among woman admitted to hospital.
Jay Z. Zhang, chairman and CEO of Shuwen Biotech, said: “Shuwen's core values are innovation, patent protection and international collaboration, and I am happy to see all three of these values are being realized through our collaboration with PerkinElmer.”
“We are now able to expand the impact of our life-improving products to an unprecedented global scale. PerkinElmer has a strong track record of commitment to maternal fetal health globally and we are proud to be working together."
Meanwhile PerkinElmer general manager Petra Furu said: “PerkinElmer is committed to improving the lives of pregnant women and children globally, and this relationship helps us leverage our strong scientific and commercial network to offer Shuwen's innovative product to more women in need all over the world.”
“There is a global need for advanced diagnostic solutions for, and we believe this point-of-care test will help address this need with respect to preeclampsia."